73792-06-0

Basic information

• Product Name: ETHYL 4-AMINO-2-FLUOROBENZOATE
• Synonyms: ETHYL 4-AMINO-2-FLUOROBENZOATE
• CAS NO: 73792-06-0
• Molecular Formula: C₉H₁₀FNO₂
• Molecular Weight: 183.1796032
• Mol File: 73792-06-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 313.865°C at 760 mmHg
• Flash Point: 143.621°C
• Appearance: /
• Density: 1.219g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C(protect from light)
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: ETHYL 4-AMINO-2-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-AMINO-2-FLUOROBENZOATE(73792-06-0)
• EPA Substance Registry System: ETHYL 4-AMINO-2-FLUOROBENZOATE(73792-06-0)

Safety Data

• Hazardous Substances Data: 73792-06-0(Hazardous Substances Data)

Usage

General Description

ETHYL 4-AMINO-2-FLUOROBENZOATE is a chemical compound with the molecular formula C9H10FNO2. It is a pale yellow solid that is soluble in organic solvents and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. ETHYL 4-AMINO-2-FLUOROBENZOATE is a derivative of benzoic acid and contains both an amino group and a fluorine atom, making it a valuable building block for the production of various organic compounds. It is important to handle and store ETHYL 4-AMINO-2-FLUOROBENZOATE with care, as it may be harmful if ingested or inhaled, and can cause skin and eye irritation upon contact.

InChI:InChI=1/C9H10FNO2/c1-2-13-9(12)7-4-3-6(11)5-8(7)10/h3-5H,2,11H2,1H3

Upstream product

• 64-17-5 ethanol 
• 1427-07-2 2-fluoro-4-nitrotoluene 
• 403-23-6 2-fluoro-4-nitrobenzoyl chloride 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 363-32-6 2-fluoro-4-nitrobenzoic acid ethyl ester 

Downstream Products

• 856253-98-0 4-[3-(8-ethynyl-2,2,4,4-tetramethyl-chroman-6-yl)-ureido]-2-fluoro-benzoic acid ethyl ester 
• 167549-34-0 ethyl 4-(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino)-2-fluorobenzoate 
• 1456692-91-3 (R)-2-(2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[1,2-a]indol-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-2-ol 
• 915087-33-1 enzalutamide 
• 1456693-15-4 ethyl 4-amino-2-(methylthio)benzoate 
• 1456693-54-1 2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[1,2-a]indol-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylic acid 
• 1456693-53-0 (2-(5-acetyl-4-(trifluoromethyl)pyrimidin-2-yl)-1-isopropyl-7-(methylsulfonyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indol-8-yl)methyl acetate 
• 1456692-94-6 (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[ 1,2-a]indol2(1 H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide 
• 1456692-95-7 (S)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[1,2-a]indol-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide 
• 1456692-93-5 ethyl 2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[1,2-a]indol-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate 
• 1456692-92-4 (S)-2-(2-(8-(hydroxymethyl)-1-isopropyl-7-(methyl sulfonyl)-3,4-dihydropyrazino[1,2-a]indol-2 (1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-2-ol 
• 1456692-90-2 (+/-)-1-(2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[1,2-a]indol-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)ethanone 
• 1456693-17-6 ethyl 5-iodo-4-(methylsulfonamido)-2-(methylthio)benzoate 
• 1456693-18-7 ethyl-5-iodo-4-(N-(methylsulfonyl)methylsulfonamido)-2-(methylthio)benzoate 

Relevant articles and documents

RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION

Modulators of retinoid acid receptor-alpha (RARα) of formula (I) are provided herein, as well as pharmaceutical compositions and methods relating thereto.

Synthesis and cardiac imaging of 18F-ligands selective for β1-adrenoreceptors

A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/ β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.